
Statins
Description
Global Statins Market to Reach US$18.1 Billion by 2030
The global market for Statins estimated at US$16.3 Billion in the year 2024, is expected to reach US$18.1 Billion by 2030, growing at a CAGR of 1.8% over the analysis period 2024-2030. Synthetic, one of the segments analyzed in the report, is expected to record a 2.0% CAGR and reach US$12.2 Billion by the end of the analysis period. Growth in the Natural segment is estimated at 1.4% CAGR over the analysis period.
The U.S. Market is Estimated at US$4.3 Billion While China is Forecast to Grow at 1.6% CAGR
The Statins market in the U.S. is estimated at US$4.3 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.9 Billion by the year 2030 trailing a CAGR of 1.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.
Global Statins Market - Key Trends and Drivers Summarized
Why Are Statins Considered Essential in Cardiovascular Disease Prevention?
Statins are considered essential in cardiovascular disease prevention as they effectively lower cholesterol levels, reduce inflammation, and stabilize arterial plaques, significantly decreasing the risk of heart attacks, strokes, and other cardiovascular events. Statins work by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in cholesterol synthesis in the liver. Widely prescribed for patients with hyperlipidemia, high cholesterol, and atherosclerosis, statins have become the gold standard for cholesterol management and cardiovascular risk reduction. With the rising prevalence of cardiovascular diseases, metabolic disorders, and aging populations, the demand for statins is increasing, making them a cornerstone in preventive healthcare and chronic disease management.
How Are Innovations in Statin Therapy and Drug Delivery Transforming the Market?
Innovations in statin therapy, drug delivery systems, and combination therapies are transforming the statin market, offering new possibilities for improving patient outcomes, adherence, and convenience. The development of high-efficacy, low-dose, and long-acting statins is addressing the need for safer, more effective cholesterol management with minimal side effects. The emergence of fixed-dose combinations (FDCs) that combine statins with other lipid-lowering agents, antihypertensives, or antidiabetic drugs is simplifying treatment regimens and improving patient adherence. Moreover, advancements in controlled-release, transdermal, and oral disintegrating tablet (ODT) formulations are enhancing drug absorption, bioavailability, and patient experience, supporting the growth of the statin market.
Which Market Segments Are Leading the Growth of the Statins Industry?
Drug types include atorvastatin, rosuvastatin, simvastatin, pravastatin, and others, with atorvastatin holding a large market share due to its high efficacy, safety profile, and widespread use. Applications of statins span hyperlipidemia, cardiovascular disease prevention, and secondary prevention, with cardiovascular disease prevention being the dominant segment due to the high prevalence of heart disease, stroke, and atherosclerosis. Distribution channels comprise hospitals, retail pharmacies, and online pharmacies, with retail pharmacies leading the market due to their accessibility, convenience, and patient reach. Geographically, North America, Europe, and Asia-Pacific are the largest markets for statins, driven by increasing healthcare expenditures, aging populations, and high awareness of cholesterol management and preventive healthcare.
What Are the Key Drivers of Growth in the Statins Market?
The growth in the statins market is driven by several factors, including rising prevalence of cardiovascular diseases, hyperlipidemia, and cholesterol disorders, technological advancements in statin formulations, drug delivery systems, and combination therapies, and the increasing awareness about preventive healthcare, heart health, and cholesterol management. The need to provide high-efficacy, low-dose, and convenient statin therapy for various patient populations is driving the demand for statins across multiple healthcare settings. Technological innovations in fixed-dose combinations, controlled-release formulations, transdermal delivery systems, and personalized medicine, coupled with advancements in clinical trials, pharmacogenomics, and real-world evidence, are enhancing the safety, efficacy, and marketability of statins, supporting market growth. The expansion of statin applications in high-risk patients, diabetes management, secondary prevention, and lifestyle interventions, along with the growing emphasis on evidence-based guidelines, patient education, and adherence programs, is creating new opportunities for market players. Additionally, the focus on developing next-generation statins, lipid-lowering agents, and combination therapies for diverse cardiovascular conditions is further propelling the growth of the statins market.
The report analyzes the Statins market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (Synthetic, Natural); Drug Class (Lovastatin, Fluvastatin, Astrovastatin, Pravastatin, Other Drug Classes)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 38 Featured) -
- AccuBioTech Co., Ltd.
- Amgen Inc.
- Biocon Ltd.
- Centrient Pharmaceuticals
- GSK Plc
- Livzon Pharmaceutical Group Inc.
- Nova Biomedical
- Novartis AG
- Pfizer, Inc.
- Terumo Corporation
We`re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Tariff Impact on Global Supply Chain Patterns
- Global Economic Update
- Statins – Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Prevalence of Cardiovascular Diseases, Hyperlipidemia, and Cholesterol Disorders Drives Demand for Statins
- Increasing Awareness About Preventive Healthcare, Heart Health, and Cholesterol Management Spurs Market Growth
- Technological Advancements in Statin Formulations, Dosage Forms, and Drug Delivery Systems Propel Innovation
- Focus on High-Efficacy, Low-Dose, and Long-Acting Statins Expands Addressable Market Opportunity
- Emergence of Combination Therapies, Fixed-Dose Combinations, and Novel Statin Variants Enhances Product Offerings
- Increasing Application of Statins in High-Risk Patient Populations, Diabetes Management, and Secondary Prevention Drives Market Adoption
- Expansion of Statin Use in Geriatric Care, Hypertension Management, and Lifestyle Interventions Spurs Market Potential
- Shift Toward Digital Health, Remote Monitoring, and Telemedicine in Statin Therapy Management Supports Market Competitiveness
- Rising Emphasis on Evidence-Based Guidelines, Clinical Trials, and Real-World Outcomes Boost Market Growth
- Growing Use of Statins in Combination with Anti-Inflammatory, Antiplatelet, and Antidiabetic Agents Enhances Market Potential
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Statins Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Statins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Statins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for Statins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for Synthetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Natural by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Natural by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Natural by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Lovastatin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Lovastatin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Lovastatin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Fluvastatin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Fluvastatin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Fluvastatin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Astrovastatin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Astrovastatin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 19: World 15-Year Perspective for Astrovastatin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Pravastatin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 21: World Historic Review for Pravastatin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 22: World 15-Year Perspective for Pravastatin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 24: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 25: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- III. MARKET ANALYSIS
- UNITED STATES
- Statins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 26: USA Recent Past, Current & Future Analysis for Statins by Type - Synthetic and Natural - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 27: USA Historic Review for Statins by Type - Synthetic and Natural Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 28: USA 15-Year Perspective for Statins by Type - Percentage Breakdown of Value Sales for Synthetic and Natural for the Years 2015, 2025 & 2030
- TABLE 29: USA Recent Past, Current & Future Analysis for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 30: USA Historic Review for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 31: USA 15-Year Perspective for Statins by Drug Class - Percentage Breakdown of Value Sales for Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes for the Years 2015, 2025 & 2030
- CANADA
- TABLE 32: Canada Recent Past, Current & Future Analysis for Statins by Type - Synthetic and Natural - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: Canada Historic Review for Statins by Type - Synthetic and Natural Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 34: Canada 15-Year Perspective for Statins by Type - Percentage Breakdown of Value Sales for Synthetic and Natural for the Years 2015, 2025 & 2030
- TABLE 35: Canada Recent Past, Current & Future Analysis for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: Canada Historic Review for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 37: Canada 15-Year Perspective for Statins by Drug Class - Percentage Breakdown of Value Sales for Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes for the Years 2015, 2025 & 2030
- JAPAN
- Statins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 38: Japan Recent Past, Current & Future Analysis for Statins by Type - Synthetic and Natural - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: Japan Historic Review for Statins by Type - Synthetic and Natural Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 40: Japan 15-Year Perspective for Statins by Type - Percentage Breakdown of Value Sales for Synthetic and Natural for the Years 2015, 2025 & 2030
- TABLE 41: Japan Recent Past, Current & Future Analysis for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: Japan Historic Review for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: Japan 15-Year Perspective for Statins by Drug Class - Percentage Breakdown of Value Sales for Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes for the Years 2015, 2025 & 2030
- CHINA
- Statins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 44: China Recent Past, Current & Future Analysis for Statins by Type - Synthetic and Natural - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: China Historic Review for Statins by Type - Synthetic and Natural Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 46: China 15-Year Perspective for Statins by Type - Percentage Breakdown of Value Sales for Synthetic and Natural for the Years 2015, 2025 & 2030
- TABLE 47: China Recent Past, Current & Future Analysis for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: China Historic Review for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 49: China 15-Year Perspective for Statins by Drug Class - Percentage Breakdown of Value Sales for Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes for the Years 2015, 2025 & 2030
- EUROPE
- Statins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 50: Europe Recent Past, Current & Future Analysis for Statins by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 51: Europe Historic Review for Statins by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 52: Europe 15-Year Perspective for Statins by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 53: Europe Recent Past, Current & Future Analysis for Statins by Type - Synthetic and Natural - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: Europe Historic Review for Statins by Type - Synthetic and Natural Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 55: Europe 15-Year Perspective for Statins by Type - Percentage Breakdown of Value Sales for Synthetic and Natural for the Years 2015, 2025 & 2030
- TABLE 56: Europe Recent Past, Current & Future Analysis for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Europe Historic Review for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 58: Europe 15-Year Perspective for Statins by Drug Class - Percentage Breakdown of Value Sales for Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes for the Years 2015, 2025 & 2030
- FRANCE
- Statins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 59: France Recent Past, Current & Future Analysis for Statins by Type - Synthetic and Natural - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: France Historic Review for Statins by Type - Synthetic and Natural Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 61: France 15-Year Perspective for Statins by Type - Percentage Breakdown of Value Sales for Synthetic and Natural for the Years 2015, 2025 & 2030
- TABLE 62: France Recent Past, Current & Future Analysis for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: France Historic Review for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 64: France 15-Year Perspective for Statins by Drug Class - Percentage Breakdown of Value Sales for Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes for the Years 2015, 2025 & 2030
- GERMANY
- Statins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 65: Germany Recent Past, Current & Future Analysis for Statins by Type - Synthetic and Natural - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: Germany Historic Review for Statins by Type - Synthetic and Natural Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 67: Germany 15-Year Perspective for Statins by Type - Percentage Breakdown of Value Sales for Synthetic and Natural for the Years 2015, 2025 & 2030
- TABLE 68: Germany Recent Past, Current & Future Analysis for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: Germany Historic Review for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 70: Germany 15-Year Perspective for Statins by Drug Class - Percentage Breakdown of Value Sales for Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes for the Years 2015, 2025 & 2030
- ITALY
- TABLE 71: Italy Recent Past, Current & Future Analysis for Statins by Type - Synthetic and Natural - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: Italy Historic Review for Statins by Type - Synthetic and Natural Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 73: Italy 15-Year Perspective for Statins by Type - Percentage Breakdown of Value Sales for Synthetic and Natural for the Years 2015, 2025 & 2030
- TABLE 74: Italy Recent Past, Current & Future Analysis for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: Italy Historic Review for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 76: Italy 15-Year Perspective for Statins by Drug Class - Percentage Breakdown of Value Sales for Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes for the Years 2015, 2025 & 2030
- UNITED KINGDOM
- Statins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 77: UK Recent Past, Current & Future Analysis for Statins by Type - Synthetic and Natural - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: UK Historic Review for Statins by Type - Synthetic and Natural Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 79: UK 15-Year Perspective for Statins by Type - Percentage Breakdown of Value Sales for Synthetic and Natural for the Years 2015, 2025 & 2030
- TABLE 80: UK Recent Past, Current & Future Analysis for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: UK Historic Review for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 82: UK 15-Year Perspective for Statins by Drug Class - Percentage Breakdown of Value Sales for Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes for the Years 2015, 2025 & 2030
- REST OF EUROPE
- TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Statins by Type - Synthetic and Natural - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: Rest of Europe Historic Review for Statins by Type - Synthetic and Natural Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 85: Rest of Europe 15-Year Perspective for Statins by Type - Percentage Breakdown of Value Sales for Synthetic and Natural for the Years 2015, 2025 & 2030
- TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Rest of Europe Historic Review for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 88: Rest of Europe 15-Year Perspective for Statins by Drug Class - Percentage Breakdown of Value Sales for Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes for the Years 2015, 2025 & 2030
- ASIA-PACIFIC
- Statins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Statins by Type - Synthetic and Natural - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: Asia-Pacific Historic Review for Statins by Type - Synthetic and Natural Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 91: Asia-Pacific 15-Year Perspective for Statins by Type - Percentage Breakdown of Value Sales for Synthetic and Natural for the Years 2015, 2025 & 2030
- TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Asia-Pacific Historic Review for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 94: Asia-Pacific 15-Year Perspective for Statins by Drug Class - Percentage Breakdown of Value Sales for Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes for the Years 2015, 2025 & 2030
- REST OF WORLD
- TABLE 95: Rest of World Recent Past, Current & Future Analysis for Statins by Type - Synthetic and Natural - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: Rest of World Historic Review for Statins by Type - Synthetic and Natural Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 97: Rest of World 15-Year Perspective for Statins by Type - Percentage Breakdown of Value Sales for Synthetic and Natural for the Years 2015, 2025 & 2030
- TABLE 98: Rest of World Recent Past, Current & Future Analysis for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Rest of World Historic Review for Statins by Drug Class - Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 100: Rest of World 15-Year Perspective for Statins by Drug Class - Percentage Breakdown of Value Sales for Lovastatin, Fluvastatin, Astrovastatin, Pravastatin and Other Drug Classes for the Years 2015, 2025 & 2030
- IV. COMPETITION
Pricing
Currency Rates